Journal of Vascular and Interventional Radiology

During , JVIR is spotlighting research focused on advancing treatment strategies and improving outcomes for patients with acute ischemic stroke.

Recent featured studies explore:
🧠 The safety and efficacy of baseline antiplatelet treatment in patients undergoing mechanical thrombectomy

🧠 The association between aortic arch calcification, ischemic stroke subtypes, and endovascular thrombectomy outcomes

These findings contribute to the growing body of evidence supporting safer, more informed stroke interventions and improved patient care in IR.

Read the studies:
Antiplatelets before mechanical thrombectomy:
https://brnw.ch/21x2Uco

Aortic arch calcification and thrombectomy outcomes:
https://brnw.ch/21x2Ucn

NEW IN JVIR: Safety and Feasibility of Yttrium-90 Radioembolization for Cirrhosis-Induced Splenomegaly and Thrombocytopenia: Results from an Investigational Device Exemption Study

🔍 Clinical Question:
This prospective study evaluated novel yttrium-90 (90Y) splenic transarterial radioembolization (TARE) for cirrhosis-associated hypersplenism and thrombocytopenia.

💡 Key Insight:
Yttrium-90 splenic transarterial radioembolization for cirrhosis-induced splenomegaly and thrombocytopenia was feasible and safe, with lung shunt fractions

NEW IN JVIR: Oncologic and Functional Outcomes of Active Surveillance and Ablative Therapy for Small Renal Masses A Systematic Review and Meta-Analysis

🔍 Clinical Question:
To compare the oncologic and renal functional outcomes of active surveillance (AS) and ablative therapy (AT) in patients with small renal masses (SRMs).

💡 Key Insight:
Active surveillance and ablative therapy demonstrated comparable oncologic outcomes, with low metastasis rates (0.6% vs 0.9%) and high cancer-specific survival (99.6% vs 93.5%).

Overall survival was higher with ablative therapy (84.8%) than active surveillance (74.0%), while both approaches demonstrated comparable long-term renal function outcomes. Subgroup analyses (T1a tumors,

NEW IN JVIR: Yttrium-90 Transarterial Radioembolization of a Hepatocellular Carcinoma via Parasitized Adrenal and Renal Capsular Arteries

🔍 Clinical Question:
To present a large hepatocellular carcinoma treated by radiation segmentectomy via parasitized adrenal arteries and a renal capsular artery achieving radiographic response and downstaging to liver transplantation.

💡 Key Insight:
In a patient with a solitary 6.5 cm HCC with minimal hepatic arterial supply, the majority of tumor supply arose from two right superior adrenal artery branches, the right middle adrenal artery, and a right renal capsular artery. Superselective Y-90 radioembolization via these parasitized vessels was performed with preparatory coil embolization of a tiny segmental branch.

Post-treatment SPECT/CT demonstrated radioactivity conforming to the tumor without extrahepatic deposition. At 3 months, tumor size decreased from 6.5 cm to 4.3 cm with minimal enhancement, and alpha-fetoprotein normalized. Explant pathology after liver transplantation at 7 months confirmed >95% tumor necrosis.

👉 Why it matters:
When HCC is predominantly supplied by extrahepatic parasitized vessels (adrenal and renal capsular arteries), meticulous vascular mapping and superselective radioembolic delivery can achieve ablative tumor dose and curative downstaging. TARE via adrenal arteries requires preparedness for acute adrenal insufficiency or hypertensive crisis.

➡️ Full Article: https://brnw.ch/21x2HuW

NEW IN JVIR: Transvenous Extrahepatic Portosystemic Shunts (TEPS): Intravascular Ultrasound-Guided Creation of Portocaval, Mesocaval, and Splenorenal Shunts

🔍 Clinical Question:
To evaluate the feasibility and long-term safety and effectiveness of intravascular ultrasound (IVUS)-guided transvenous extrahepatic portosystemic shunt (TEPS) creation for patients unsuitable for transjugular intrahepatic portosystemic shunt (TIPS) creation.

💡 Key Insight:
Intravascular ultrasound (IVUS)-guided creation of portocaval, mesocaval, and splenorenal transvenous extrahepatic portosystemic shunts was technically successful in 100% of 23 patients, with 100% 1-year primary patency and 100% 3-year primary assisted patency. One Grade 3 periprocedural adverse event of acute kidney injury occurred. No Grade >2 major hemorrhage or hollow viscus organ injury. Delayed hepatopulmonary and portopulmonary syndromes, attributed to decreased hepatic clearance of splanchnic vasoactive substances, occurred in 2 patients.

👉 Why it matters:
Transvenous extrahepatic portosystemic shunts may offer a last resort for portomesenteric decompression in patients with obliterated portomesenteric vasculature or an obstructed intrahepatic path. The IVUS-guided transvenous technique is entirely endovascular and provides real-time visualization of retroperitoneal vessels and organs while avoiding open surgery and risk of traversing hollow viscus organs.

➡️ Full Article:
https://brnw.ch/21x2CIF

JVIR continues strong momentum with a 30% increase in submissions, faster review timelines, and expanded global engagement. With streamlined workflows and rapid publication, JVIR remains a leading voice in interventional radiology.

Explore more at https://brnw.ch/21x2qGA.

The new May issue of JVIR is now live!

This issue highlights active surveillance versus ablation for small renal masses, IVUS-guided TEPS creation for portal hypertension, and novel yttrium-90 splenic radioembolization research in cirrhosis-associated hypersplenism.

Explore the latest research now here: https://brnw.ch/21x2nVB

The May JVIR audio abstracts are now available!

These short-form summaries highlight key findings and clinical insights from recent publications, offering an efficient, accessible way to stay connected to the latest advances in the field.

Listen now: https://brnw.ch/21x2hvN.

Many thanks to the JVIR Editorial Board for the countless hours they dedicate each year to advancing patient care through high‑quality published research. We also want to extend special appreciation to our Co‑Editors‑in‑Chief, Charles E. Ray Jr., MD, PhD, FSIR, and Brian F. Funaki, MD, FSIR, for guiding a seamless transition to JVIR’s fully online platform. This shift ensures timely, broad, and equitable access to the highest‑quality IR research and clinical education. Explore enhanced digital features for authors and readers, and join us in supporting a more sustainable future for the journal. https://brnw.ch/21x1RXe

NEW IN JVIR: Superselective Transarterial Embolization Using Imipenem/Cilastatin Sodium for Plantar Fasciitis Refractory to Conservative Management

🔍 Clinical Question:
To assess the feasibility, safety, and effectiveness of superselective transarterial embolization (TAE) using imipenem/cilastatin sodium for plantar fasciitis (PF) refractory to conservative management.

💡 Key Insight:
In this single-center retrospective study including 12 patients with chronic painful plantar fasciitis refractory to conservative management, branches of posterior tibial artery supplying the area of maximal pain were superselectively embolized using imipenem/cilastatin sodium.

Technical success was achieved in 91.7% (11 of 12) procedures, while clinical success was achieved in 72.7% (8 of 11) of the technically successful procedures with no early/remote complications.

There was significant improvement in the visual analog scale score on day 1 after procedure, which was sustained over 1 year of follow-up.

👉 Why it matters:
Superselective TAE using imipenem/cilastatin sodium is feasible, safe, and effective in alleviating pain associated with plantar fasciitis refractory to conservative management, with a low risk of adverse events, offering a minimally invasive option for patients who have exhausted standard therapies.

➡️ Full Article:
https://brnw.ch/21x1Q0h